{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:16:48Z","timestamp":1792088208169,"version":"4.4.0"},"reference-count":121,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tirzepatide is a novel glucose\u2010dependent insulinotropic polypeptide\/glucagon\u2010like peptide 1 (GLP\u20101) receptor agonist approved in the United States as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes and under investigation for use in chronic weight management, major adverse cardiovascular events and the management of other conditions, including heart failure with preserved ejection fraction and obesity and non\u2010cirrhotic non\u2010alcoholic steatohepatitis. The Phase 3 SURPASS 1\u20105 clinical trial programme was designed to assess efficacy and safety of once\u2010weekly subcutaneously injected tirzepatide (5, 10 and 15\u2009mg), as monotherapy or combination therapy, across a broad spectrum of people with type 2 diabetes. Use of tirzepatide in clinical studies was associated with marked reductions of glycated haemoglobin (\u22121.87 to \u22122.59%, \u221220 to \u221228\u2009mmol\/mol) and body weight (\u22126.2 to \u221212.9\u00a0kg), as well as reductions in parameters commonly associated with heightened cardiometabolic risk such as blood pressure, visceral adiposity and circulating triglycerides. In SUPRASS\u20102, these reductions were greater than with the GLP\u20101 receptor agonist semaglutide 1\u00a0mg. Tirzepatide was well tolerated, with a low risk of hypoglycaemia when used without insulin or insulin secretagogues and showed a generally similar safety profile to the GLP\u20101 receptor agonist class. Accordingly, evidence from these clinical trials suggests that tirzepatide offers a new opportunity for the effective lowering of glycated haemoglobin and body weight in adults with type 2 diabetes.<\/jats:p>","DOI":"10.1111\/dom.14831","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T05:33:34Z","timestamp":1659677614000},"page":"3-17","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0679-3203","authenticated-orcid":false,"given":"Christophe","family":"De Block","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital University of Antwerp  Edegem Belgium"},{"name":"Faculty of Medicine and Health Sciences, Laboratory of Experimental Medicine and Paediatrics (LEMP) University of Antwerp  Wilrijk Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6998-6811","authenticated-orcid":false,"given":"Clifford","family":"Bailey","sequence":"additional","affiliation":[{"name":"Health and Life Sciences Aston University  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3056-0047","authenticated-orcid":false,"given":"Carol","family":"Wysham","sequence":"additional","affiliation":[{"name":"Section of Endocrinology and Metabolism MultiCare Rockwood Clinic  Spokane WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hemmingway","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl Elaine","family":"Allen","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Peleshok","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.19"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0806"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05181-w"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.01.039"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-9028"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2016.1168291"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.021"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009158"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194127"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05482"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05487"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-4887.2007.tb00329.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2017.31"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S008"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1407"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33102-1"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30068-3"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.67929"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01919-X"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2415"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2062"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.10.008"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.016"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa2032271"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0968"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.12.004"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1759"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164116679775"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20662"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057143"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012512"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1123"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2019.170183"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116186"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-002-0878-6"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-0943-x"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199205143262003"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S009"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaspect.17.3.183"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69705-5"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo.141.6.7490"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91194-9"},{"issue":"1","key":"e_1_2_9_45_1","first-page":"327","article-title":"Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon\u2010like peptide\u20101 (GLP\u20101)\u2010(7\u201036) amide in type 2 (noninsulin\u2010dependent) diabetic patients","volume":"81","author":"Willms B","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0135"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2020.02.006"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo.133.6.8243312"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(94)90016-7"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.289009"},{"issue":"6","key":"e_1_2_9_51_1","first-page":"E603","article-title":"GIP increases insulin receptor affinity and cellular sensitivity in adipocytes","volume":"249","author":"Starich GH","year":"1985","journal-title":"Am J Physiol"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-37-5-826"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2040-1124.2010.00022.x"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140532"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.09.009"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa863"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(22)00085\u20107"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146353"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.2337\/db22-714-P"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.2337\/db20-969-P"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.2337\/db22-338-OR"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01012-2"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01140-3"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14110"},{"key":"e_1_2_9_66_1","unstructured":"Mounjaro [package insert].Indianapolis IN: Eli Lilly and Company;2022.https:\/\/pi.lilly.com\/us\/mounjaro-uspi.pdf?s=pi"},{"key":"e_1_2_9_67_1","unstructured":"Adlyxin [package insert].Bridgewater NJ: Sanofi US;2021.https:\/\/products.sanofi.us\/adlyxin\/adlyxin.pdf"},{"key":"e_1_2_9_68_1","unstructured":"Bydureon [package insert].Wilmington DE: AstraZeneca Pharmaceuticals LP;2022.https:\/\/den8dhaj6zs0e.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/6b02db6d-7a95-4a90-88ae-5f5ac7397755\/6b02db6d-7a95-4a90-88ae-5f5ac7397755_viewable_rendition__v.pdf"},{"key":"e_1_2_9_69_1","unstructured":"Byetta [package insert].Wilmington DE. AstraZeneca Pharmaceuticals LP;2022.https:\/\/den8dhaj6zs0e.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/ce8afab9-2b45-436d-957c-a73978d09e93\/ce8afab9-2b45-436d-957c-a73978d09e93_viewable_rendition__v.pdf"},{"key":"e_1_2_9_70_1","unstructured":"Ozempic [package insert].Bagsvaerd Denmark: Novo Nordisk A\/S;2022.https:\/\/www.novo-pi.com\/ozempic.pdf"},{"key":"e_1_2_9_71_1","unstructured":"Rybelsus [package insert].Bagsvaerd Denmark: Novo Nordisk A\/S;2022.https:\/\/www.novo-pi.com\/rybelsus.pdf"},{"key":"e_1_2_9_72_1","unstructured":"Victoza [package insert].Plainsboro NJ: Novo Nordisk Inc.;2021.https:\/\/www.novo-pi.com\/victoza.pdf"},{"key":"e_1_2_9_73_1","unstructured":"Trulicity [package insert].Indianapolis IN: Eli Lilly and Company;2022.https:\/\/pi.lilly.com\/us\/trulicity-uspi.pdf"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01443-4"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02188-7"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0078"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13979"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32260-8"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00077-8"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00070-5"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-016-0134-z"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1205"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3080"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S006"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.4158\/CS-2019-0472"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14572"},{"key":"e_1_2_9_88_1","unstructured":"DaviesMJ FriasJP RosenstockJ et al.Efficacy and safety of tirzepatide versus semaglutide once weekly as add\u2010on therapy to metformin in people with type 2 diabetes (SURPASS\u20102). Presention at the: the American Diabetes Associaton \u2010 81st Annual Scientific Sessions; June 25\u2010292021; Virtual Meeting."},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17050633"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31624"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.08.061"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20170261"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30110-8"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30092-X"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00070"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1625"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1472-y"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01707-4"},{"key":"e_1_2_9_102_1","unstructured":"US Food and Drug Association.Diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.2008.https:\/\/www.fda.gov\/media\/71297\/download"},{"key":"e_1_2_9_103_1","unstructured":"European Medicines Agency.Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus.2010.https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-clinical-investigation-medicinal-products-treatment-prevention-diabetes-mellitus_en.pdf"},{"key":"e_1_2_9_104_1","unstructured":"US Food and Drug Administration.Guidance for industry. Type 2 diabetes mellitus: evaluating the safety of new drugs for improving glycemic control.2020."},{"key":"e_1_2_9_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-009-0038-4"},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1432"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0490-6"},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001986"},{"key":"e_1_2_9_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13847"},{"key":"e_1_2_9_110_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3070"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds16-0026"},{"key":"e_1_2_9_112_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_2_9_113_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405"},{"key":"e_1_2_9_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14640"},{"key":"e_1_2_9_115_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_9_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14775"},{"key":"e_1_2_9_117_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-05039-w"},{"key":"e_1_2_9_118_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917"},{"key":"e_1_2_9_119_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_9_120_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_9_121_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13028"},{"key":"e_1_2_9_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14831","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14831","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:31:34Z","timestamp":1761877894000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/dom.14831"],"URL":"https:\/\/doi.org\/10.1111\/dom.14831","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"assertion":[{"value":"2022-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}